AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04218708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASSIST (the Alcohol, Smoking and Substance Involvement Screening)
Description: The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
Study NCT04218708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
Study NCT06738472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home based exercises
Description: given exercises to the participants
Study NCT04218708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIDA Standardized Research E-cigarettes (SREC)
Description: NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver >300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine.
Study NCT05069558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational PFO Closure Device
Description: Occlutech Flex II PFO Closure Device
Study NCT05069558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care PFO Closure Device
Description: Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Study NCT06074536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient-centered approach training
Description: face to face training of general practitioner of interventional arm
Study NCT05388760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
Study NCT06105684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Pill
Description: Will be given once per day by mouth
Study NCT00775476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
Study NCT00775476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
Study NCT04759404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Oscillation Treatment
Description: Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
Study NCT04759404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Treatment
Description: Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
Study NCT05048862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve excitability study
Description: Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at >32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
Study NCT05048862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation (TMS)
Description: In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
Study NCT05048862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI acquisition and image analysis
Description: fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
Study NCT05973669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL Remote Care
Description: Remote cochlear implant support
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Given abiraterone
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given apalutamide
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide
Description: Given darolutamide
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given degarelix
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Given enzalutamide
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Given goserelin
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histrelin
Description: Given histrelin
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Given leuprolide
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06378866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo watchful waiting
Study NCT06378866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo watchful waiting
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06378866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given prednisone
Study NCT06378866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06378866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix
Description: Given relugolix
Study NCT06378866 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06378866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06378866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Given triptorelin
Study NCT04234386 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: GammaPod Radiation
Description: The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
Study NCT05827614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-355
Description: Oral CHK1 inhibitor
Study NCT05827614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: EGFR Inhibitor
Study NCT05827614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: FGFR1-4 Inhibitor
Study NCT04205032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test of the different devices integrated in cardiospace II
Description: The different devices included in CARDIOSPACE II will be tested~* Electrocardiogram~* Vascular Doppler~* LaserDoppler and iontophoresis~* Brachial blood pressure~* Continuous blood pressure recorded at the finger level~* Ultrasound~* Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)
Study NCT06463119 — intervention group
Intervention type: OTHER
Intervention: Collection of data in a registry
Description: The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
Study NCT05323929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Endoscopic Submucosal Dissection for early gastric cancer
Study NCT05487469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
Study NCT05487469 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blank Control
Description: the Control group did not receive Thymosin alpha 1 or any placebo.
Study NCT05265988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
Study NCT06009380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
Study NCT06009380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation
Description: The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
Study NCT05091632 — intervention group
Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Undergo EEG
Study NCT05091632 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05887687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P3
Description: 68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study NCT05000775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G-Niib
Description: G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
Study NCT05000775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.5mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT05661357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Combined With Fruquintinib
Description: Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
Study NCT06335173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug
Description: Intravenous sabirnetug
Study NCT06335173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo
Study NCT06746142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Deep inspiration breath hold radiotherapy
Description: Participants will be trained for 2-3 days for obtaining the desired breathing cycle by trained technologists. No extra equipment will be needed. At first, they will be assured and asked to relax. Then instructed to breath in and out twice followed by a slow, deep breath in to a comfortable higher level than normal and to hold it for at least 20 seconds then again breath normally. Once they are ready with expected breath holding, simulation will be done. Treatment will also be given in this breath holding position.
Study NCT05672199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Subcutaneous (SC) injection
Study NCT05672199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study NCT06746142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Free breathing radiotherapy
Description: Patient will be advised for free breathing during simulation and treatment.
Study NCT06746038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear Hearing Aid
Description: Extended wear hearing aid means that the device is worn 24 hours per day, 7 days a week for months at a time. However, this study will only fit devices on participants for one testing session lasting 2 hours.
Study NCT06374498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-NIRAF
Description: Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
Study NCT06123663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTVA
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
Study NCT06123663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
Study NCT05165485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin 175 mcg administered once daily for 84 days via nebulization
Study NCT05165485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
Study NCT05165485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revefenacin Placebo
Description: Placebo for Revefenacin administered once daily for 84 days via nebulization
Study NCT05165485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Placebo
Description: Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
Study NCT05067634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
Study NCT06352333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular ultrasound guided brachial plexus block
Description: two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
Study NCT05368090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation
Description: Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
Study NCT05368090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA of left adrenal tumour in PA, debulking group
Description: Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
Study NCT05368090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation
Description: Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h